EP2413696A4 - Compositions pour le traitement de la maladie d'alzheimer - Google Patents

Compositions pour le traitement de la maladie d'alzheimer

Info

Publication number
EP2413696A4
EP2413696A4 EP10759174A EP10759174A EP2413696A4 EP 2413696 A4 EP2413696 A4 EP 2413696A4 EP 10759174 A EP10759174 A EP 10759174A EP 10759174 A EP10759174 A EP 10759174A EP 2413696 A4 EP2413696 A4 EP 2413696A4
Authority
EP
European Patent Office
Prior art keywords
alzheimer
disease
compositions
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10759174A
Other languages
German (de)
English (en)
Other versions
EP2413696A1 (fr
Inventor
Jorge Galvez
Javier Llompart
David Land
Giulio Pasinetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Medisyn Technologies Inc
Original Assignee
Medisyn Technologies Inc
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medisyn Technologies Inc, Mount Sinai School of Medicine filed Critical Medisyn Technologies Inc
Publication of EP2413696A1 publication Critical patent/EP2413696A1/fr
Publication of EP2413696A4 publication Critical patent/EP2413696A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP10759174A 2009-04-03 2010-04-05 Compositions pour le traitement de la maladie d'alzheimer Withdrawn EP2413696A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21182109P 2009-04-03 2009-04-03
PCT/US2010/001041 WO2010114636A1 (fr) 2009-04-03 2010-04-05 Compositions pour le traitement de la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
EP2413696A1 EP2413696A1 (fr) 2012-02-08
EP2413696A4 true EP2413696A4 (fr) 2012-10-24

Family

ID=42828621

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10759174A Withdrawn EP2413696A4 (fr) 2009-04-03 2010-04-05 Compositions pour le traitement de la maladie d'alzheimer

Country Status (4)

Country Link
EP (1) EP2413696A4 (fr)
AU (1) AU2010232923A1 (fr)
CA (1) CA2759187A1 (fr)
WO (1) WO2010114636A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2731608T3 (en) * 2011-07-13 2018-06-18 Microbiotix Inc Inhibitors of the bacterial type III secretion system
CN102391262A (zh) * 2011-07-20 2012-03-28 延边大学 含3-羧烷基罗丹宁衍生物的抗菌化合物
WO2014186450A2 (fr) * 2013-05-14 2014-11-20 The Board Of Regents Of The University Of Texas System Inhibiteurs très puissants de porc-épic
WO2022120150A1 (fr) * 2020-12-03 2022-06-09 Duke University Dérivés d'amiloride et procédés d'utilisation de ceux-ci pour le traitement d'infections virales

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001455A1 (fr) * 1990-07-25 1992-02-06 Luedke Hans Werner Medicament contre les maladies degeneratives des fonctions cerebrales du type de la maladie d'alzheimer et troubles du systeme cholinergique
WO2003070737A1 (fr) * 2002-02-21 2003-08-28 Polimeri Europa S.P.A. Complexes de borate tris-pyrazolyle de nickel et leur utilisation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002432A1 (fr) * 1987-09-16 1989-03-23 Taiho Pharmaceutical Company, Limited Derives de thienopyrimidine
EP0361489A3 (fr) * 1988-09-30 1991-06-12 Chugai Seiyaku Kabushiki Kaisha Composés de 3,4-diaminoquinoline et de pyridine
NZ248573A (en) * 1992-09-10 1996-02-27 Lilly Co Eli 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions
US5948819A (en) * 1994-04-06 1999-09-07 Shionogi & Co., Ltd α-substituted phenylacetic acid derivative, its production and agricultural fungicide containing it
DE19548146C1 (de) * 1995-12-21 1997-11-20 Basf Ag Tris(pyrazolyl)boratmetallkomplex-Katalysatoren und deren Verwendung
CA2309177A1 (fr) * 1997-11-06 1999-05-20 Stephen Allan Smith Composes de pyrimidinone et compositions pharmaceutiques les renfermant
US6559155B1 (en) * 1998-08-21 2003-05-06 Smithkline Beecham P.L.C. Pyrimidinone derivatives for the treatment of atherosclerosis
JP2004532234A (ja) * 2001-04-27 2004-10-21 バーテックス　ファーマシューティカルズ　インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
US7049318B2 (en) * 2003-07-25 2006-05-23 Amgen Inc. Substituted heterocyclic compounds and methods of use
BRPI0510340A (pt) * 2004-04-28 2007-10-30 Pfizer derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina
WO2006047254A1 (fr) * 2004-10-22 2006-05-04 Regents Of The University Of Minnesota Ensembles de proteines beta-amyloides oligomeres et utilisations de ceux-ci
US7718683B2 (en) * 2006-07-14 2010-05-18 Chemocentryx, Inc. Triazolyl phenyl benzenesulfonamides
WO2008128982A1 (fr) * 2007-04-18 2008-10-30 Probiodrug Ag Nouveaux inhibiteurs
EP2193117A1 (fr) * 2007-07-16 2010-06-09 Wyeth a Corporation of the State of Delaware Inhibiteurs de production de beta amyloide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001455A1 (fr) * 1990-07-25 1992-02-06 Luedke Hans Werner Medicament contre les maladies degeneratives des fonctions cerebrales du type de la maladie d'alzheimer et troubles du systeme cholinergique
WO2003070737A1 (fr) * 2002-02-21 2003-08-28 Polimeri Europa S.P.A. Complexes de borate tris-pyrazolyle de nickel et leur utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010114636A1 *

Also Published As

Publication number Publication date
WO2010114636A1 (fr) 2010-10-07
CA2759187A1 (fr) 2010-10-07
EP2413696A1 (fr) 2012-02-08
AU2010232923A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
IL264736B (en) Pharmaceutical preparations containing zonisamide for use in the treatment of diseases related to Alzheimer's disease
ZA201100034B (en) Pharmaceutical compositions for treatment of parkinson's disease
EP2151435A4 (fr) Composition pharmaceutique pour le traitement de la maladie d'alzheimer
EP2382176A4 (fr) Utilisation d'analogues de curcumine contenant de l'azote pour le traitement de la maladie d'alzheimer
ZA201006868B (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
EP2312945A4 (fr) Dérivés de purine pour le traitement de la maladie d alzheimer
IL213259A0 (en) Composition for the use to treat alzheimer's disease
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
HK1169941A1 (zh) 治療外周血管疾病的組合物
EP2707369A4 (fr) Compositions et procédés pour traiter la maladie d'alzheimer
IL200342A (en) A drug used to treat cartilage disease
EP2268647A4 (fr) Composés et compositions pour la détection et le traitement de la maladie d'alzheimer et des troubles associés
EP2312946A4 (fr) Dérivés de pyrimidine pour le traitement de la maladie d alzheimer
EP2485733A4 (fr) Procédés pour le traitement de la maladie d'alzheimer
EP2429992A4 (fr) Traitement du trouble cognitif léger et de la maladie d'alzheimer
EP2378879A4 (fr) Dérivés du triazole pour traitement de la maladie d'alzheimer
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
PL2429507T3 (pl) Kompozycja farmaceutyczna wolna od fosforanów do leczenia jaskry
EP2568811A4 (fr) Traitement du tcl et de la maladie d'alzheimer
EP2379075A4 (fr) Dérivés de triazole pour le traitement de la maladie d'alzheimer
EP2398789A4 (fr) Inhibiteurs de bêta-sécrétase de type spiropyrrolidine pour le traitement de la maladie d'alzheimer
EP2349308A4 (fr) Composés pour le traitement de la maladie d alzheimer
EP2413696A4 (fr) Compositions pour le traitement de la maladie d'alzheimer
IL217149A0 (en) Compositions and methods for treating parkinson's disease
EP2391379A4 (fr) Composé et procédé de traitement de la maladie d'alzheimer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MOUNT SINAI SCHOOL OF MEDICINE

Owner name: MEDISYN TECHNOLOGIES, INC.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120926

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/69 20060101ALI20120920BHEP

Ipc: A61P 25/28 20060101ALI20120920BHEP

Ipc: A61K 31/415 20060101ALI20120920BHEP

Ipc: A61K 31/4709 20060101ALI20120920BHEP

Ipc: A61K 31/513 20060101ALI20120920BHEP

Ipc: A01N 43/64 20060101AFI20120920BHEP

Ipc: A61K 31/426 20060101ALI20120920BHEP

Ipc: A61K 31/4196 20060101ALI20120920BHEP

Ipc: A61K 31/404 20060101ALI20120920BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130426